Hormonal
Tirzepatide (5-15 mg once weekly) produces superior weight loss (16-22.5% mean reduction) compared to placebo and other GLP-1 RAs by acting as a dual GLP-1 and GIP receptor agonist.
Tirzepatide is a once-weekly injection that significantly reduces body weight (16-22.5%) in adults with overweight or obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to increase satiety and reduce food intake. Treatment starts at a low dose (2.5 mg) and increases every 4 weeks to minimize side effects like nausea. It is most effective when combined with lifestyle changes, including a caloric deficit and regular physical activity.
Tirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors... In SURMOUNT-1, tirzepatide (5, 10, and 15 mg) led to 16–22.5% mean weight loss (WL) in people with overweight/obesity (without T2D)... Tirzepatide at doses 5, 10 and 15 mg demonstrated greater HbA1c and weight reduction compared to these GLP-1 RAs.
Why this rating
Based on multiple large-scale Phase 3 randomized controlled trials (SURMOUNT-1, -2, -3, -4).
Source
Tirzepatide for overweight and obesity management
Malak Hamza et al. · Expert Opinion on Pharmacotherapy · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →